Leslie C Costello*
Department of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry; and the University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA
Received Date: June 22, 2022
Published Date: August 3, 2022
*Corresponding author: Leslie C Costello, Ph.D., Distinguished University Professor, Department of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry; and the University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA - 21201. Tel: 410 706 7618; E-mail: [email protected]
Citation: Costello LC. (2022). Clioquinol Zinc Ionophore for Terminating Advanced “Decreased Zinc” Testosterone-Dependent Prostate Cancer: A Case Report. Mathews J Case Rep. 7(2):73.
Copyrights: Costello LC © (2022).
In 2019, Costello et al. published the first successful treatment Case Report of a patient who presented with testosterone-dependent prostate cancer. That cancer is a “decreased-zinc” malignancy. The treatment was clioquinol zinc ionophore (3% Clioquinol Cream), which terminated the patient’s malignancy.
This second Case Report corroborates the 2019 Case report in employing clioquinol to terminate testosterone-dependent prostate cancer in patients. The two patient cases provide evidence that clioquinol will likely be effective for other patients. Now, oncologists and urologists have efficacious systemic chemotherapy for their testosterone-dependent prostate cancer patients. Then, for the first time, many or most of the 314,500 men in the U.S., and the 10 million men worldwide, who die of prostate cancer every year, can now be treated with clioquinol and cured of that cancer. We must make it happen.
Keywords: prostate cancer; testosterone cancer; prolactin cancer; treatment; clioquinol; cabergoline